κ-Opioid system in uremic pruritus: Multicenter, randomized, double-blind, placebo-controlled clinical studies

Journal of the American Society of Nephrology

Volumn 16, Issue 12, 2005, Pages 3742-3747

  Wikström, Björn ^a   Gellert, Ryszard ^b   Ladefoged, Søren D ^c   Danda, Yasuaki ^d   Akai, Masahiko ^d   Ide, Kaoru ^d   Ogasawara, Midori ^d   Kawashima, Yoshiharu ^d   Ueno, Koki ^d   Mori, Akio ^d   Ueno, Yuji ^d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c Rigshopspitalet   (Denmark)

^d TORAY INDUSTRIES INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KAPPA OPIATE RECEPTOR; NALFURAFINE; PLACEBO; ANTIPRURITIC AGENT; NALTREXONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEMODIALYSIS; HUMAN; INSOMNIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; UREMIA; VERTIGO; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; FOLLOW UP; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION TEST; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PROBABILITY; REFERENCE VALUE; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT;

ADULT; AGED; ANTIPRURITICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NALTREXONE; PROBABILITY; PRURITUS; RECEPTORS, OPIOID, KAPPA; REFERENCE VALUES; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UREMIA;

EID: 33645952393     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005020152     Document Type: Article

References (24)

1. Gilchrest BA, Stern RS, Steinman TI, Brown RS, Arndt KA, Anderson WW: Clinical features of pruritus among patients undergoing maintenance hemodialysis. Arch Dermatol 118: 154-156, 1982
2. Evans RW, Manninen DL, Garrison LP Jr, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG: The quality of life of patients with end-stage renal disease. N Engl J Med 312: 553-559, 1985
3. Balaskas EV, Oreopoulos DG: Uremic pruritus. Dial Transplant 21: 192-244, 1992
4. Robertson KE, Mueller BA: Uremic pruritus. Am J Health Syst Pharm 53: 2159-2170, 1996
5. Goicoechea M, de Sequera P, Ochando A, Andrea C, Caramelo C: Uremic pruritus: An unresolved problem in hemodialysis patients. Nephron 82: 73-74, 1999
6. Barrett BJ, Vavasour HM, Major A, Parfrey PS: Clinical and psychological correlates of somatic symptoms in patients on dialysis. Nephron 55: 10-15, 1990
7. Carmichael AJ, McHugh MI, Martin AM: Renal itch as an indicator of poor outcome. Lancet 337: 1225-1226, 1991
8. Murphy M, Carmichael AJ: Renal itch. Clin Exp Dermatol 25: 103-106, 2000
9. Jedras M, Bataa O, Gellert R, Ostrowski G, Wojtaszek E, Lange J, Oledzka M: Acupressure in the treatment of uremic pruritus. Dial Transplant 32: 8-10, 2001
10. Yosipovitch G, Greaves MW, Schmelz M: Itch. Lancet 361: 690-694, 2003
11. Pan ZZ: mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 19: 94-98, 1998
12. Cousins MJ, Mather LE: Intrathecal and epidural administration of opioids. Anesthesiology 61: 276-310, 1984
13. Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, Nagase H: Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 477: 29-35, 2003
14. Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, Kawamura K, Endoh T, Utsumi J, Kamei J, Tanaka T, Nagase H: Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 435: 259-264, 2002
15. Cho YL, Liu HN, Huang TP, Tarng DC: Uremic pruritus: Roles of parathyroid hormone and substance P. J Am Acad Dermatol 36: 538-543, 1997
16. Whitehead A, Whitehead J: A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10: 1665-1677, 1991
17. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7: 177-188, 1986
18. Bergstrom J, Alvestrand A, Bucht H, Gutierrez A: Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol 25: 1-6, 1986
19. Schmelz M: A neural pathway for itch. Nat Neurosci 4: 9-10, 2001
20. Schmelz M: Itch-Mediators and mechanisms. J Dermatol Sci 28: 91-96, 2002
21. Ko MCH, Lee H, Song MS, Sobczyk-Kojiro K, Mosberg HI, Kishioka S, Woods JH, Naughton NN: Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther 305: 173-179, 2003
22. Kumagai H, Saruta T, Matsukawa S, Utsumi J: Prospects for a novel kappa-opioid receptor agonist, TRK-820, in uremic pruritis. In: Itch, Basic Mechanisms and Therapy, edited by Yosipovitch G, Greaves MW, Fleischer Jr AB, McGlone F, New York, Marcel Dekker Inc, 2004, pp 279-286
23. Odou P, Azar R, Luyckx M, Brunet C, Dine T: A hypothesis for endogenous opioid peptides in uraemic pruritus: Role of enkephalin. Nephrol Dial Transplant 16: 1953-1954, 2001
24. Pan ZZ, Tershner SA, Fields HL: Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor. Nature 389: 382-385, 1997